Tenet Healthcare Corporation reports developments across a diversified healthcare services business that combines ambulatory surgery, hospital operations and healthcare-services outsourcing. Its care delivery network includes United Surgical Partners International, which operates ambulatory surgery centers and surgical hospitals, along with acute care and specialty hospitals, outpatient facilities, employed physician networks and a global business center in Manila.
Recurring news themes for THC include quarterly earnings, financial outlooks, same-facility revenue trends, Ambulatory and Hospital segment performance, payer-mix and expense-management commentary, and capital or ownership actions involving Conifer Health Solutions. Company updates also cover Conifer's revenue cycle management and value-based care services for hospitals, health systems, physician practices, employers and other clients, as well as Tenet's presentations at healthcare investor conferences.
Tenet (NYSE: THC) reported strong Q4 2025 and full-year results, with Q4 net income $371M ($4.22/diluted share) and Adjusted EBITDA $1.183B. FY2025 free cash flow was $2.53B and net debt/Adjusted EBITDA improved to 2.25x. Tenet provided FY2026 guidance: Adjusted EBITDA $4.485B–$4.785B and diluted EPS $29.60–$32.27. Tenet announced a Jan 27, 2026 agreement with CommonSpirit delivering $1.9B in payments and recording ~$1.65B contract termination revenue in 2026.
Tenet Healthcare (NYSE: THC) completed a transaction with CommonSpirit to resume full ownership of Conifer Health Solutions effective January 1, 2026.
Key terms include approximately $1.9 billion in payments from CommonSpirit over three years, a $540 million redemption, a reduction in redeemable noncontrolling interest of ~$885 million, and an increase to additional paid-in capital of ~$305 million. Tenet estimates 2025 Adjusted EBITDA at the upper end of its $4.47–$4.57 billion guidance. Conifer will continue serving CommonSpirit through year-end 2026. A management webcast is scheduled for February 2, 2026.
Tenet Healthcare (NYSE: THC) will report its fourth quarter 2025 results before the market opens on Wednesday, February 11, 2026.
The company will hold a conference call at 9:00 a.m. CT (10:00 a.m. ET) the same day. A live webcast and audio archive will be available in the investor relations section at www.tenethealth.com/investors.
Ryder (NYSE: R) announced the election of Tammy Romo to its board of directors, effective January 5, 2026. Romo will serve on Ryder’s Audit and Finance Committees.
Romo retired as executive vice president and chief financial officer of Southwest Airlines on April 1, 2025 after more than 30 years with the company and a decade overseeing corporate financial functions. She has served as an independent director of Tenet Healthcare (NYSE: THC) since 2015.
Tenet Healthcare (NYSE: THC) priced a private offering upsized to $2.25 billion of notes on November 3, 2025: $1.5 billion 5.500% senior secured first lien notes due November 15, 2032 and $0.75 billion 6.000% senior notes due November 15, 2033.
Closing is expected on November 18, 2025. Net proceeds, with cash on hand, will redeem all $1.5 billion outstanding 6.250% second lien notes due February 2027 and partially redeem $0.75 billion of 6.125% senior notes due October 2028. First lien notes are secured; senior notes are unsecured and will be offered only to qualified institutional buyers or outside U.S. persons under Regulation S.
Tenet Healthcare (NYSE: THC) announced private placements of $1.5 billion of senior secured first lien notes due 2032 and $0.5 billion of senior notes due 2033 to refinance $2.0 billion of outstanding notes.
The first lien notes will be guaranteed by certain subsidiaries and secured by a pledge of subsidiary ownership interests; the senior notes will be unsecured and structurally subordinated to subsidiary liabilities. Offerings are private to QIBs and non-U.S. persons under Rule 144A and Regulation S and are subject to pricing and customary closing conditions.
Tenet (NYSE: THC) reported third-quarter 2025 results with Q3 net income $342M ($3.86 diluted) and Adjusted diluted EPS $3.70, up 26.3% year-over-year. Consolidated Adjusted EBITDA was $1.099B, up 12.4% versus Q3 2024; Ambulatory Adjusted EBITDA was $492M, up 12.1%.
Year-to-date free cash flow was $2.163B, operating cash flow $2.809B, and net debt/Adjusted EBITDA improved to 2.30x. Tenet repurchased 0.6M shares for $93M in Q3 and 7.8M shares for $1.188B year-to-date. Management raised FY 2025 Adjusted EBITDA outlook to $4.47B–$4.57B (midpoint +$50M).
Tenet Healthcare (NYSE:THC) has scheduled the release of its Q3 2025 financial results for Tuesday, October 28, 2025, before market opening. The company will host a conference call at 9:30 a.m. CT (10:30 a.m. ET) to discuss the results. Investors can access both the live webcast and audio archive through Tenet's investor relations website.
Tenet Healthcare (NYSE:THC) announced its upcoming participation in the 2025 Wells Fargo Healthcare Conference. The presentation is scheduled for September 3, 2025, at 9:30 a.m. Eastern Time.
Investors can access the live webcast and audio archive through Tenet's investor relations website. The replay will remain available for 30 days following the presentation.
Tenet Healthcare (NYSE:THC) and its subsidiary USPI have been named foundational sponsors of the American Association of Orthopaedic Surgeons' (AAOS) inaugural Launchpad Program. The 20-month initiative is designed to support postgraduate year 5 (PGY5) orthopaedic surgery residents in their transition from residency to practice.
The program, launched as a pilot at the AAOS Annual Meeting in March 2025, will support three cohorts of PGY5 resident members over the next three and a half years. It focuses on fellowship navigation, preparation for American Board of Orthopaedic Surgery examinations, and building foundations for long-term success. AAOS plans to expand the program to include all PGY4 and PGY5 residents after the pilot phase.